backOn April 13, 2021, the Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) issued a statement on the Johnson & Johnson COVID-19 Vaccine. Both the CDC and FDA are reviewing data involving six reported cases of a rare and severe type of blood clot, cerebral venous sinus thrombosis, in individuals after receiving the vaccine. These six cases occurred 6 to 14 days after vaccination among women between the ages of 18 and 48.
As of April 12, more than 6.8 million doses of the Johnson & Johnson vaccine have been administered in the United States, and these adverse effects appear to be extremely rare. However, the CDC and FDA have recommended a pause on the administration of the vaccine out of an abundance of caution pending review by the CDC Advisory Committee on Immunization Practices (ACIP).
Click here for more details.
Click here for our COVID-19 vaccines updates.